- Home
- XPER vs ALMS Comparison
XPER vs ALMS Comparison
Compare XPER & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- ALMS
- Stock Information
- Founded
- XPER 1990
- ALMS 2021
- Country
- XPER United States
- ALMS United States
- Employees
- XPER N/A
- ALMS N/A
- Industry
- XPER Semiconductors
- ALMS
- Sector
- XPER Technology
- ALMS
- Exchange
- XPER Nasdaq
- ALMS NYSE
- Market Cap
- XPER 463.5M
- ALMS 469.0M
- IPO Year
- XPER 2003
- ALMS 2024
- Fundamental
- Price
- XPER $9.00
- ALMS $7.66
- Analyst Decision
- XPER Strong Buy
- ALMS Strong Buy
- Analyst Count
- XPER 3
- ALMS 6
- Target Price
- XPER $19.00
- ALMS $29.60
- AVG Volume (30 Days)
- XPER 318.5K
- ALMS 122.0K
- Earning Date
- XPER 02-26-2025
- ALMS 02-15-2025
- Dividend Yield
- XPER N/A
- ALMS N/A
- EPS Growth
- XPER N/A
- ALMS N/A
- EPS
- XPER N/A
- ALMS N/A
- Revenue
- XPER $508,559,000.00
- ALMS N/A
- Revenue This Year
- XPER N/A
- ALMS N/A
- Revenue Next Year
- XPER $2.28
- ALMS N/A
- P/E Ratio
- XPER N/A
- ALMS N/A
- Revenue Growth
- XPER N/A
- ALMS N/A
- 52 Week Low
- XPER $6.89
- ALMS $6.75
- 52 Week High
- XPER $12.29
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- XPER 35.66
- ALMS N/A
- Support Level
- XPER $8.82
- ALMS N/A
- Resistance Level
- XPER $9.22
- ALMS N/A
- Average True Range (ATR)
- XPER 0.32
- ALMS 0.00
- MACD
- XPER -0.18
- ALMS 0.00
- Stochastic Oscillator
- XPER 10.00
- ALMS 0.00
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.